RxDoctor Payments Data

Louie Leyva

Family · El Paso, TXNPI 1154325603

Payments from drug & device makers

$389in general payments, 2019–2025

Across 19 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$143
  • Novartis$81
  • Amgen$52
  • Lilly USA, LLC$45
  • Novo Nordisk$22
  • Bayer$16
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$389100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$389 in reported general payments places this provider in the 50th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$38,321
Medicare patients
169
Services billed
1,525

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide88$132,175
FarxigaDapagliflozin Propanediol95$105,005
JanuviaSitagliptin Phosphate40$54,556
MounjaroTirzepatide46$49,792
EliquisApixaban48$49,204
JardianceEmpagliflozin29$40,573
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$33,596
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog20$22,558
TrulicityDulaglutide16$17,707
Lantus SolostarInsulin Glargine,hum.Rec.Anlog87$13,300
Advair HfaFluticasone Propion/Salmeterol22$7,303
KerendiaFinerenone11$7,022
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$6,508
Levemir FlexpenInsulin Detemir24$5,662
Fluticasone-SalmeterolFluticasone Propion/Salmeterol40$5,551

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$22$132,17588 claims
Lilly USA, LLCMounjaro, Trulicity$45$67,49962 claims
GSKTrelegy Ellipta$16$33,59634 claims
BayerKerendia$16$7,02211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 15,456 family providers in Texas.

Other family in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →